The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

@article{Garrison2011TheSM,
  title={The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis},
  author={Kendra Garrison and Tobias Hahn and Wen-Cherng Lee and Leona E. Ling and Andrew D. Weinberg and Emmanuel T. Akporiaye},
  journal={Cancer Immunology, Immunotherapy},
  year={2011},
  volume={61},
  pages={511-521}
}
Effective tumor immunotherapy may require not only activation of anti-tumor effector cells, but also abrogation of tumor-mediated immunosuppression. The cytokine TGF-β, is frequently elevated in the tumor microenvironment and is a potent immunosuppressive agent and promoter of tumor metastasis. OX40 (CD134) is a member of the TNF-α receptor superfamily and ligation by agonistic antibody (anti-OX40) enhances effector function, expansion, and survival of activated T cells. In this study, we… CONTINUE READING
Highly Cited
This paper has 33 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Why has active immunotherapy not worked in lung cancer?

Annals of oncology : official journal of the European Society for Medical Oncology • 2015
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Similar Papers

Loading similar papers…